See also article by Ruetten et al. [11] (pages 444-453) in this issue.
through both cGMP-dependent and reactive oxygen species (ROS)-dependent pathways, effects which could account for its anti-hypertrophic actions [6, 7] . NO also inhibits cardiac fibroblast proliferation, an effect analogous to the cGMPmediated actions of ANP and BNP [5, 9] .
The development of cardiac hypertrophy in vivo in response to chronic pressure overload is a complex process that involves alterations in cardiomyocyte size, structure, and function as well as extracellular matrix remodeling [10] . Chronic hypertrophy usually progresses to left ventricular (LV) dilatation and failure. Different components of the cardiac hypertrophic phenotype, for example hypertrophy, interstitial fibrosis, and contractile dysfunction, are capable of being independently regulated. Translating the actions of NO determined in cultured cells to the intact heart and animal is therefore not straightforward, and it remains unclear what the roles of different NOS isoforms and different cell types are with respect to pressure-overload hypertrophy in vivo.
In the current issue of the Journal, Ruetten and colleagues [11] report the effects of pressure overload induced by abdominal aortic banding in eNOS knockout mice and wild-type controls. Consistent with the aforementioned in vitro studies, these authors found that banded eNOS À/À mice had greater hypertrophy than wild-type mice as assessed by echocardiographic wall thickness or myocyte cross-sectional area. They also found evidence of increased interstitial fibrosis in the banded eNOS À/À animals together with worse systolic and diastolic LV function compared to wild-type banded mice. Interestingly, however, Ruetten et al. [11] found that, in banded eNOS À/À mice, the left ventricle failed to dilate during chronic pressure overload despite greater hypertrophy and contractile dysfunction, whereas banded wild-type mice showed significant increases in both end-diastolic and end-systolic LV dimensions. Thus, banded eNOS À/À mice developed concentric LV hypertrophy whereas wild-type animals developed eccentric LV remodeling. The authors concluded that banded eNOS À/À mice developed a severe restrictive hypertrophy. A potential limitation of the study was the failure to use littermate controls, since it is clear that non-littermate wild-type mice of the same strain are not perfect controls. Nonetheless, the phenotype reported by Ruetten et al. [11] is reminiscent of that found in rats chronically treated with the non-selective NOS inhibitor N G -nitro-l-arginine methyl ester (l-NAME), which also developed concentric LV remodeling with reduced chamber dimensions [12] . Likewise, Barouch et al. [3] recently reported that double-knockout eNOS À/À / nNOS À/À mice developed a restrictive cardiac phenotype with aging. These results suggest a divergence between the (inhibitory) effects of eNOS on cardiomyocyte hypertrophy and interstitial fibrosis versus actions that may promote LV dilatation; i.e., in eNOS À/À mice, hypertrophy is enhanced but LV dilatation is inhibited. In contrast to these results, Ichinose et al. [13] reported that in response to transverse thoracic aortic banding (which induced a greater overload than that induced in the study by Ruetten et al. [11] ), eNOS À/ À mice developed greater LV dilatation than wild-type bands. The same group also reported that LV remodeling post-MI was greater in eNOS À/À mice than wild-type mice [14] . It is therefore unclear whether the effects of eNOS on chamber remodeling vary depending upon the nature or intensity of the stimulus. However, in the study by Ichinose et al. [13] , LV dilatation was prevented by treating eNOS À/À mice with hydralazine to normalize elevated blood pressure, suggesting that the dilatation may have been a secondary effect.
The mechanisms underlying the divergent effects of eNOS deletion on LV hypertrophy versus dilatation after aortic banding were not explored in the current study. The enhancement of LV hypertrophy is consistent with prior in vitro results and could involve mechanisms such as activation of the calcineurin-NFAT pathway. On the other hand, LV dilatation usually involves activation of matrix metalloproteases (MMPs). Whether both of these effects involve eNOS in cardiomyocytes or whether endothelial cell eNOS may also play a role is an interesting question. It is also important to establish whether the differences between eNOS À/À and wild-type mice are indeed due to the loss of eNOS-derived NO in the former group or whether indirect effects, such as altered interaction with ROS or alterations in allosteric regulators or co-factors for the enzyme [4] , are involved. The study by Ruetten et al. [11] highlights the potential for divergent regulation of different aspects of the cardiac hypertrophic phenotype as well as raises questions regarding the underlying mechanism(s) of the findings reported. More needs also to be learned about the cellspecific effects of eNOS in cardiac hypertrophy.
